# CM-PharmE B4 — Final Evaluation Report

## Purpose

B4 evaluates CM-PharmE by turning the design and evaluation procedures reported in the published conference paper and the later journal manuscript under review into repository-native, inspectable evidence. The repository does not treat manuscript prose as validation by itself; it records provenance, executes what can be executed, and preserves the evidential boundary of what remains qualitative, illustrative, or unverified.

The stable semantic baseline remains `v1.0.0`. B4 does not assign a new semantic version.

## Inputs

B4 used the canonical 39-concept / 40-relation / 5-domain registries, the B3 cleaned formal ontology and cardinality registry, the two CM-PharmE publication records, eight manuscript competency questions, eight manuscript OntoUML-informed anti-pattern categories, the vaccine-distribution scenario, and publication-derived expert-review observations.

## 1. Structural and traceability validation

A computational cross-check was run over the B3 canonical reference ontology and registries.

**Result: PASS — 28/28 checks.**

Validated items include 39 canonical concept classes; 39 OWL object properties plus one generalization record (`CMPE-R0006`); five domains; stable-ID agreement between registries and the formal graph; 40 unique relation IDs; source/target and cardinality-registry agreement; lifecycle agreement; definitions, primary domains, and stereotypes for all concepts; valid relation domain/range references; 42 qualified cardinality restrictions; absence of historical converter cardinality classes; and graph equivalence of the four B3 reference serializations to the 1,086-triple canonical graph.

This establishes strong structural traceability, not semantic completeness or OWL DL consistency.

## 2. Executable competency questions

The eight competency questions reported in the journal manuscript were implemented as SPARQL queries and executed against the B3 ontology plus a constructed vaccine-distribution sample.

**Result: 8/8 bounded expected outcomes PASS.**

- CQ1 enterprise structure/capability/governance: PASS
- CQ2 ecosystem collaboration/partnership: PASS
- CQ3 process and clinical participation: PASS
- CQ4 governance/pharmacovigilance traceability: PASS, with manuscript-to-formal traceability note
- CQ5 digital-enabler connections: PASS
- CQ6 business-architecture / ontology traceability sample: PASS as a traceability query, not BACM conformance
- CQ7 five-domain application coverage: PASS as illustrative coverage, not adoption evidence
- CQ8 bounded extension scenario: PASS; 32 existing core classes across all five domains and zero scenario-defined classes

The executable queries improve reproducibility, but they do not transform CQ7 or CQ8 into empirical validation.

## 3. Vaccine-distribution scenario

A machine-readable Turtle sample was created using **only existing CM-PharmE classes and canonical relations**.

Schema check:

- 33 scenario individuals;
- 32 distinct core classes instantiated;
- all 5 domains represented;
- 34 CM-PharmE relation assertions;
- 0 unknown class assertions;
- 0 unknown relation predicates;
- 0 explicit domain/range compatibility violations.

**Result: PASS — bounded illustrative instantiation.**

### Publication-to-formal traceability findings

B4 identified several places where the journal manuscript's illustrative prose is semantically broader or more direct than the current formal relation graph:

1. The manuscript states that Governance Policy / Compliance Requirement constrain operational constructs, while the current graph does not encode a direct policy/compliance-to-business-process constraint relation.
2. The manuscript describes Pharmacovigilance Requirement as constraining Adverse Event Reporting Procedure; the canonical graph instead has `CMPE-R0031` to Post-Market Surveillance Activity and `CMPE-R0035` from surveillance to the reporting procedure.
3. The manuscript describes RWE Platform as supporting surveillance and surveillance information as informing risk management; the current graph instead explicitly connects RWE Platform to Pharmacovigilance Requirement and directly to Risk Management Activity.
4. EHR information exchange and blockchain traceability are plausible application interpretations, but the current formal properties are narrower than those prose descriptions.

B4 **does not modify the ontology to force agreement with manuscript prose**. These are recorded as traceability findings for subsequent semantic disposition.

## 4. OntoUML-informed anti-pattern re-evaluation

The eight historical categories were rechecked using repository heuristics plus targeted semantic inspection.

### Confirmed clean within the checked scope

- Type–Role Confusion
- Event as Object
- Mode vs. Attribute Confusion
- Relation as Class

### Historical low-risk finding retained

- Overloaded Association: no single stable property was found with multiple domain/range definitions, but generic `material relation` terminology remains provisional.

### Historical minor findings retained

- **Relator without Mediation / mediation specificity:** Supply Chain Relationship still lacks clear mediation to participant role types; `CMPE-R0024` connects it to a Blockchain Ledger kind.
- **Part–Whole Misuse:** the Public–Private Partnership Structure → Ecosystem Governance Entity relation remains a semantic-review item.

### New B4 review candidates

- **Healthcare Provider (`CMPE-C0021`)** is stereotyped as a Role but has no explicit or inherited mediation relation in the formal graph. This weakens the earlier blanket “Role without Relator = Clean” publication observation and should be semantically reviewed.
- **Clinical Pathway (`CMPE-C0018`) → Pharmaceutical Business Process (`CMPE-C0015`)** through `CMPE-R0029 is part of` crosses Relator → Perdurant categories and merits targeted mereological review.

No critical issue requiring immediate redesign of the five-domain architecture was identified.

## 5. Expert / semantic evidence

The later manuscript's four-expert qualitative review has been normalized into repository evidence without inventing new quotations, scores, demographics, or consensus statistics. Documented feedback concerned terminology precision, role-definition clarity, and retention of the five-domain structure.

**Result: PARTIAL.**

The evidence is now traceable, but B4 did not perform a new independent expert panel. It therefore supports research provenance and refinement history rather than independent semantic validation.

## 6. Logical / reasoner validation

B4 prepared the intended ROBOT/HermiT validation. Java is available and the current official ROBOT release was identified as `v1.9.10`, but the runtime does not contain ROBOT/HermiT/ELK/JFact/Owlready2 and external binary/package download is blocked.

**Result: NOT VERIFIED / BLOCKED.**

No structural or SPARQL result is substituted for a DL reasoner result. B4 therefore makes no claim of OWL DL consistency, absence of unsatisfiable classes, or complete logical soundness. This is the most important remaining computational validation gap.

## 7. Evaluation status by layer

See [`b4-evaluation-matrix.md`](b4-evaluation-matrix.md) for the E1–E9 evidence matrix.

- E1 Syntax — PASS
- E2 Logic — NOT VERIFIED / BLOCKED
- E3 Structure — PASS
- E4 Ontological — CONDITIONAL
- E5 Semantic / Expert — PARTIAL
- E6 Data / Mapping — PASS, bounded
- E7 Competency Questions — PASS, bounded
- E8 Application — PARTIAL / illustrative
- E9 Reproducibility — PARTIAL

## Final conclusion

B4 materially strengthens CM-PharmE evaluation compared with publication-only evidence. It converts the eight competency questions into executable tests, creates a machine-readable cross-domain scenario, computationally verifies structural and registry traceability, and turns historical anti-pattern and expert observations into versioned evidence.

At the same time, B4 exposes useful discrepancies that a manuscript-centered evaluation did not make explicit. In particular, some scenario prose is broader than the canonical relation graph, and at least two additional ontology-review candidates deserve explicit disposition.

The appropriate conclusion is therefore:

**B4 evaluation evidence package: PASS with open, explicitly recorded findings.**

**CM-PharmE stable-release readiness: NOT YET.**

No semantic change should be made merely to make the ontology match manuscript prose. The next step is to run a reproducible DL reasoner workflow and then decide—separately and traceably—whether the identified role/mediation, part-whole, and scenario/formal discrepancies require ontology changes or only documentation clarification.
